| Term 
 | Definition 
 
        |   MOA: These drugs block the fast sodium channels in the myocardium. They show intermediate dissociation from the sodium channels and lengthen the refractory period to stop the arrhythmia. The sodium channel is responsible for depolarization in the myocardium |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |     Quinidine Procainamide (Prontestyl®) Disopyramide (Norpace®) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | No brand name   Used to treat supraventricular and ventricular arrhythmias   80% bound to protein   SE: Thrombocytopenia   One of the first antiarrhythmics and is still used today   Class IA |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Pronestyl®   Used mainly for ventricular arrhythmias   Metabolized by N-acetyl transferase to N-acetylprocainamide, 50% is excrete unchanged in the urine   SE: Systemic Lupus erythamatous (SLE) like syndrome   Class IA |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Norpace®   Used primarily to prevent ventricular tachycardia and premature ventricular contractions   Half life=6.7 hours   SE: Has anticholinergic side effects   Class IA |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |     MOA: Blocks the fast sodium channels. Dissociate rapidly from the sodium channel and have the lowest potency |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |     Lidocaine (Xylocaine®) Mexiletine (Mexitil®) Tocainide (Tonocard®) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Xylocaine®   Used primarily for premature ventricular contractions and ventricular arrhythmias, originally used as a local anesthetic     Class IB |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Mexitil®   Used as long term prophylaxis against ventricular tachycardia   Available as an oral formulation     Class IB |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Tonocard®       Used chronically, available as an oral formulation        Class IB |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |     MOA: Block fast acting sodium channels, dissociate slowly from the sodium channels, therefore are the most potent   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |     Flecainide (Tambocor®) Propafenone (Rythmol®)   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Tambocor®     Good for suppressing ventricular automaticity by slowing AV conduction   Has local anesthetic activity   Class IC |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Rythmol®     Used for supraventricular arrhythmias   Orally active, has weak beta blocking activity     Class IC |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Beta Blockers     MOA: Stabilizes or depresses the membrane through inhibition of adrenergic stimulation to the heart, slows the heart rate and ectopic tachycardias |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |     Propranolol (Inderal®) Esmolol (Brevibloc®) Acebutolol (Sectral®) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Inderal®   Used for the treatment of supraventricular arrhythmias and ventricular tachycardias   Major metabolite: Napthoxylactic acid    Class II |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Brevibloc®    Used for inoperative and other arrhythmias   Short acting, IV only     Class II |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Sectral®     Used for premature ventricular contractions and ventricular tachycardia   Active metabolite: diacetolol   Class II |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Repolarization Prolongators     MOA: Prolong action potential thus increasing the refractory period of the membrane action potential. May also block potassium and sodium channels |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   Amiodarone (Cordarone®) Dronedarone (Multaq®) Sotalol (Betapace®) Ibutilide (Covert®) Dofetilide (Tikosyn®) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Cordarone®   Used to control refractory ventricular tachycardias, prevent ventricular fibrillation, and atrial fibrillation (non-FDA)   SE: Pulmonary toxicity, thyroid toxicity, interstitial fibrosis, phototoxicity, optic neuritis   Class III |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Multaq®   Used for persistent atrial fibrillation and atrial flutter   SE: Less pulmonary side effects, thyroid effects, and neurological activity than Amiodarone     Class III |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Betapace®     Used for ventricular arrhythmias and atrial fibrillation   Available orally     Class III |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Corvert®   Blocks potassium channel and /or slow sodium channels   Used to convert atrial fibrillation and atrial flutter to normal sinus rhythm   SE: Torsade de pointe   Class III |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Tikosyn®   Used for the conversion and management of atrial flutter to normal sinus rhythm   SE: Torsade de pointe     Class III |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Calcium Channel Blockers    MOA: These block slow inward current of Ca2+ ions during phase 2 of action potential, Slow down AV conduction and the sinus rate 
 
 SE: Bradycardia, hypotension, headache, edema 
 
 Class IV |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |       Verapamil (Calan®, Isoptin®)  Diltiazem (Cardizem®, Dilacor®)      |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Calan®, Isoptin®     Used to control atrial and paroxysmal tachycardia       Class IV |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Cardizem®, Dilacor®     Used to control atrial and paroxysmal tachycardia       Class IV |  | 
        |  | 
        
        | Term 
 
        |         Miscellaneous Antiarrhythmics |  | Definition 
 
        |     Adenosine (Adenocard®) Magnesium Sulfate Potassium |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Adenocard®   MOA: Activates inward rectifier potassium; blocks calcium current Nucleoside that occurs naturally in the body 
 
 
 Miscellaneous |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | No Brand Name     MOA: Poorly understood; interacts with Na+, K+ ATPase, K+ and Ca2+ channels 
 
 Miscellaneous |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | No Specific Brand Name     MOA: Increases K+ permeability, K+ currents       Miscellaneous |  | 
        |  |